Skip to content
Head to head

Jazz Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: JAZZ · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

JAZZ +35.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals trades cheapest on trailing earnings; Vertex Pharmaceuticals earns the most per share.
JAZZVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price230.26515.02
Change today-2.62%-1.08%
1-year return+31.0%+22.0%
Market cap$14.78B$130.58B
52-week range156.95 – 266.38412.27 – 568.67
Valuation
P/E (TTM)68.1233.14
P/E percentile, own 5-yr range88th99th
P/B3.536.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-5.8415.32
Net profit (TTM)$-374.86M$3.88B
Revenue (TTM)$4.72B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+10.4%+11.8%
Gross margin89.1%85.5%
Operating margin24.0%33.1%
Net margin4.4%30.7%
Free cash flow (TTM)$1.41B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership102.9%96.8%
Insider activity (12mo)12 buy / 38 sell28 buy / 22 sell
Short interest (% of float)8.9%1.9%
Analyst consensus100% buy (16)95% buy / 5% hold (21)
Analyst price target$307 (+33%)$624 (+21%)
StockVane view
StockVane Quant RatingC (76)C (68)
Company
Employees2,8906,400
Founded20031989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.